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acne, ovarian dysfunction, and infertility.[4,6,7] Although 
anovulation is an obvious cause of infertility in 
polycystic ovary syndrome, growing evidence suggests 
that endometrial receptivity also contributes to infertility 
of these patients.[1,7,8]
Endometrial receptivity means the ability of the uterine 
lining to accept an implanting embryo, resulting in a 
successful pregnancy. It seems that a shortened or absent 
receptive endometrium is the main cause of conception 
delay and lack of pregnancy.[9,10] Successful implantation 
depends on the regulation of protein networks that are 
INTRODUCTION
Polycystic ovary syndrome is one of the most common 
endocrine disorders in premenopausal women and the 
most frequent cause of ovulatory infertility.[1-3] Prevalence 
of this condition in women of the reproductive age is 
approximately between 5% and 10%.[1,4,5] Polycystic 
ovary syndrome as a complex disorder is associated 
with several health complications including obesity, 
hyperandrogenism, metabolic syndrome, hirsutism, 
Background: Women with polycystic ovary syndrome have lower pregnancy rates, possibly due to the decreased uterine receptivity. 
Successful implantation depends on protein networks that are essential for cross-talk between the embryo and endometrium. 
Apolipoprotein A1 has been proposed as a putative anti-implantation factor. In this study, we evaluated apolipoprotein A1 expression 
in human endometrial tissues. Materials and Methods: Endometrial apolipoprotein A1 messenger RNA (mRNA) and protein 
expression were investigated using quantitative real-time polymerase chain reaction (PCR) and Western blot. The distribution of 
apolipoprotein A1 was also detected by immunostaining. Samples were obtained from 10 patients with polycystic ovary syndrome 
and 15 healthy fertile women in the proliferative (on day 2 or day 3 before ovulation, n = 7) and secretory (on days 3-5 after ovulation, 
n = 8) phases. Results: Endometrial apolipoprotein A1 expression was upregulated in patients with polycystic ovary syndrome 
compared to normal subjects. However, apolipoprotein A1 expression in the proliferative phase was significantly higher than in the 
luteal phase (P value < 0.05). Conclusion: It seems that differentially expressed apolipoprotein A1 negatively affects endometrial 
receptivity in patients with polycystic ovary syndrome. The results showed that apolipoprotein A1 level significantly changes in the 
human endometrium during the menstrual cycle with minimum expression in the secretory phase, coincident with the receptive 
phase (window of implantation). Further studies are required to clarify the clinical application of this protein.
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essential for communication between the nascent embryo 
and endometrium. Several studies have been performed 
to provide potential genes and protein candidates for 
endometrial receptivity. However, none of them have been 
verified as a clinical biomarker.[1,2] Apolipoprotein A1 is 
the predominant protein for high density lipoproteins.[2,11] 
Apolipoprotein A1 is a primary acceptor for cholesterol in 
extrahepatic tissues.[2,11] Apolipoprotein A1 is dysregulated 
in diverse tissues and body fluids in a variety of diseases.[12,13] 
Recent works showed that apolipoprotein A1 may also play 
a role in endometrial receptivity and it has been identified 
as a putative anti-implantation factor secreted by the 
differentiating endometrium.[2,11,13] A proteomic analysis of 
the endometrium from women with repeated implantation 
failure and normal fertile women showed a significantly 
higher apolipoprotein A1 expression in patients with 
repeated implantation failure.[14] Further studies confirmed 
that upregulation of apolipoprotein A1 is upregulated in 
the endometrium of women with unexplained infertility.[2] 
The abovementioned evidences provide a potential role 
for apolipoprotein A1 in female infertility associated with 
endometrium disturbances. Therefore, in the present study 
the possible in vivo role of apolipoprotein A1 in endometrial 
receptivity of patients with polycystic ovary syndrome was 
investigated.
MATERIALS AND METHODS 
Patients and tissue selection
Human endometrial samples were obtained from 
10 patients with polycystic ovary syndrome and 15 healthy 
fertile women in the proliferative (on day 2 or day 3 before 
ovulation, n = 7) and secretory (on days 3-5 after ovulation, 
n = 8) phases. Daily urinary luteinizing hormone levels were 
monitored using an ovulation prediction kit. The mean age of 
the participants was 26 (range: 18-35) years. The participants 
did not receive any form of hormonal therapy and none 
of them used an intrauterine contraceptive device during 
the previous 3 months. Patients with chronic anovulation, 
clinical and/or biochemical signs of hyperandrogenism, 
and those who were polycystic in the ultrasound scanning 
of ovaries were diagnosed as polycystic ovary syndrome 
(Rotterdam ESHRE/ASRM-sponsored polycystic ovary 
syndrome Consensus Workshop Group, 2004). Endometrial 
biopsies were taken using Pipelle catheters under sterile 
conditions. Each biopsy was divided into three pieces. The 
first portion was transferred to a cryotube containing 1 mL 
RNAlater (Ambion, Austin, TX, USA), for RNA extraction. 
Another portion was fixed in formalin for histological 
dating. The last part was dry-frozen at –80°C for protein 
extraction. Approval for the use of tissues was prepared by 
the local ethics committee and written informed consent was 
obtained prior to the sample collection (IUMS, No. 19950).
RNA extraction, cDNA synthesis, and reverse transcription 
polymerase chain reaction 
Total RNA was extracted from endometrial samples 
by homogenization in trizol reagent (Sigma Pool, UK), 
according to the manufacturer’s instructions. RNA samples 
were treated with DNase I (Fermentas, Sankt Leon-Rot, 
Germany) to remove genomic DNA contamination. First-
strand cDNA synthesis was performed using oligo dT 
primers (Metabion, Martinsried, Bavaria, Germany) and 
was reverse-transcribed using SuperScript II (200 U/µl, 
fermentase). Negative controls were prepared without an 
enzyme (nonreverse transcribed controls, RT controls). The 
reverse transcription polymerase chain reaction (RT-PCR) 
was performed with the prepared cDNA, Platinum Blue 
PCR SuperMix (Invitrogen, Paisley, Scotland, UK) and 
the forward and reverse primers for apolipoprotein A1 
(Metabion, Martinsried, Bavaria, Germany). The following 
primer pairs were used: β-actin forward 5’-TGA CCC AGA 
TCA TGT TTG AGA CC-3’ and β-actin reverse 5’-GGA GGA 
GCA ATG ATC TTG ATC TTC-3,’ apolipoprotein A1 forward 
5’-CCCAGTTGTCAAGGAGCTTT-3,’ and apolipoprotein 
A1 reverse 5’-TGGATGTGCTCAAAGACAGC-3.’ The 
amplification was performed for 40 cycles under the 
following setting: 95° for 30 s, 60° for 1 min, and 72° for 
1 min. All experiments included RT controls as negative 
controls. To separate PCR products, 10 µl of each sample 
was resolved on a 1.2% agarose gel and electrophoresis was 
performed with 1x tris-acetate-EDTA (TAE) buffer and a 
voltage of 95 V for 30-40 min. The bands were visualized by 
using an ultraviolet transillumination. The RT-PCR products 
were sequenced to confirm the identity of the amplified 
product. β-actin was used as a housekeeping control and 
its expression was checked between the three groups.[15] 
Quantitative real-time polymerase chain reaction (qPCR)
qPCR was performed using cDNA prepared from endometrial 
samples. qPCR reactions were performed in triplicates using 
an ABI Prism 7300 Sequence Detector (Applied Biosystems, 
Foster City, California, USA) in a total volume of 20 µl 
containing 250 ng cDNA, 5 pmol gene-specific primers, and 
SYBR Green reagent (Applied Biosystems) with ROX dye as a 
passive control for signal intensity. The thermal cycle profile 
followed 50 cycles at 95° for 30 s, 60° for 30 s, and 72° for 30 s. 
Melting curves of PCR reactions were monitored to ensure 
that there is one single PCR product and no primer dimmer. 
Standard curves were used to assess primers efficiency. 
The qPCR data were analyzed using the comparative 
CT method. In brief, the difference in cycle time (ΔCT) 
was determined as the difference between the number of 
cycles required for amplification of the test gene and the 
reference housekeeping gene, human β-actin. Then, ΔΔCT 
was assessed as the difference between the groups. The fold 
change (FC) was calculated as 2-ΔΔ.[15]
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Protein extraction
Briefly, endometrial tissue samples were homogenized in 1 
mL of TRI reagent (Sigma Pool, UK) (VWR) for ∼1 min. The 
total protein was extracted using TRI reagent (Invitrogen 
15596-026) and quantified by Bradford’s assay with a 
standard curve generated using a human serum albumin/
gamma globulin (Fluka SP8119).[16]
Western blotting 
Normal endometrial tissue in proliferative and secretory 
phases as well as endometrial tissues of women with 
polycystic ovary syndrome was used for apolipoprotein 
A1 expression analysis. Samples, containing 40 µg of 
total protein, were subjected to 12% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
at 100V and transferred to polyvinylidene fluoride 
(PVDF) membrane (Bio-Rad, USA) by a wet transfer 
system (Bio-Rad, USA) at 20V overnight. Transferred 
blots were blocked with 5% BSA and 0.1% Tween-20 
(Sigma-Aldrich, St. Louis, MO, USA). Afterward, blots 
were incubated overnight at 4°C with primary antibody 
against apolipoprotein A1 (1:5000; Abcam ab17278, 
Cambridge, Cambridgeshire, UK) and β-actin (1:10000; 
Sigma-Aldrich, St. Louis, MO, USA). The blots were then 
washed three times, each time for 20 min with TBST 
and were incubated with the secondary antibody, HRP-
conjugated anti-mouse antibody (Abcam, ab195891) for 
1 h at room temperature. After three washes, each time 
for 20 min with TBST, the blots were visualized by the 
chemiluminescent peroxidase substrate (ECL Advance, 
GE Healthcare, UK) in a dark room and were exposed to 
x-ray films (GE, 28906835). Subsequently, the films were 
scanned with densitometer (GS-800, Bio-Rad, USA). The 
values were normalized to β-actin. For a negative control, 
the blots were incubated with nonimmunized serum as 
primary antibody.[16]
Immunohistochemistry
The antibody used in the experiment was obtained 
from Abcam (Cambridge, Cambridgeshire, UK). It was 
monoclonal antibody specific for apolipoprotein A1 
(catalogue no. ab17278). Tissue samples were fixed in 
10% neutral buffered formalin for 18-24 h, embedded in 
paraffin, and cut in 4 µm. Formal in-fixed sections were 
deparaffinized with xylosine twice for 5 min followed by 
rehydration in graded ethanol. Endogenous peroxidase 
activity was blocked with 3% v/v hydrogen peroxidase in 
methanol for 20 min. Antigen retrieval on these sections 
was performed by microwave irradiation for 10 min in 10 
mmol/L sodium citrate pH = 6.0. Sections were allowed to 
cool for 20 min and then washed in phosphate buffer saline 
(PBS), then stained using a Vectastain Elite ABC peroxidase 
kit (Vector Laboratories Ltd., UK). 
In addition, to avoid nonspecific binding, an avidin/biotin 
blocking kit was used. Briefly, the slides were blocked for 1 
h at room temperature in PBS containing 0.2% appropriate 
serum and 25% avidin supplied in the blocking kit. The 
block was removed and the slides were incubated overnight 
at 4°C in primary antibody at an appropriate dilution 
using antibody diluent media (Dakocytomation Ltd., 
Ely, UK) and 250 ml biotin per mL of diluted antibody. 
Binding was visualized by incubation with peroxidase 
substrate 3-amino-9-ethylcarbazole (AEC) for 10 min, 
washed in distilled water for 3 min, and counterstained 
in 10% hematoxylin for 10 min. Slides were washed in tap 
water for 2 min and mounted with Aquamount (VWR). 
Control sections were obtained by the blocking of primary 
antibody with the corresponding specific peptide using a 
20-fold excess of blocking peptide. Immunostained sections 
were examined using an Olympus BH2 microscope at ×250 
magnification (Olympus, London, UK).
Statistical analysis
Western-blot images in each group were analyzed by 
Image J software. Also, relative apolipoprotein A1 gene 
expression quantities were compared between the groups. 
The threshold cycle values were normalized against the 
threshold value of human β-actin. Differences in normalized 
gene and protein expression values between the samples 
were tested for the significance using analysis of variance 
(ANOVA) statistical test. The results were expressed as 
mean ± standard error of the mean (SEM). P values <0.05 
were considered to be statistically significant. 
RESULTS
Apolipoprotein A1 immunoblotting analysis
Demographic characteristics, hormonal and clinical 
parameters of polycystic ovary syndrome, and the control 
subjects are summarized in Table 1. A representative 
western blotting analysis of apolipoprotein A1.
Table 1: Demographic characteristics, hormonal, and 
clinical parameters of polycystic ovary syndrome and 
control subjects
Characteristic PCOS group 
(n = 10)
Control group 
(n = 15)
P 
value*
Age (years), mean±SD 27.31±4.06 27.79±3.89 0.87
BMI (kg/m2), mean±SD 26.42±3.99 25.21±4.19 0.80
Menstruation type n (%)
Regular 4 (40) 15 (100) 0.00
Irregular 6 (60) 0 (0) 0.00
LH (mU/mL), mean±SD 7.12±3.96 5.01±3.37 0.69
FSH (mU/mL), mean±SD 6.29±1.90 8.54±0.37 0.51
LH/FSH ratio, mean±SD 1.24±0.70 0.64±0.33 0.03
Testosterone (ng/mL), 
mean±SD
2.61±0.73 1.30±0.53 0.05
*T test or chi-square test; BMI = Body mass index; SD = Standard deviation; FSH = 
Follicle stimulating hormone; LH = Luteinizing hormone
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Protein expression in endometrial specimens is shown in 
Figure 1. Western blot analysis showed a significantly higher 
apolipoprotein A1 protein expression in the endometrium 
of patients with polycystic ovary syndrome compared to 
normal ones. However, expression of this protein in the 
proliferative phase was significantly higher than in the 
luteal phase.
Reverse transcription polymerase chain reaction 
Figure 2 shows the result of RT-PCR for mRNA expression 
of apolipoprotein A1 and human β actin genes in the 
human endometrium of normal women and patients with 
polycystic ovary syndrome. All amplified products were 
of the expected size for that particular gene. There was no 
amplified product in the control samples, which indicate 
the lack of genomic DNA contamination. Human β actin 
as the housekeeping gene showed a stable gene expression 
between the different groups. 
Quantitative real-time polymerase chain reaction 
Apolipoprotein A1 gene expression in endometrial 
biopsies was evaluated using quantitative real-time PCR 
[Figure 3]. There was a significantly higher expression 
of apolipoprotein A1 in patients with polycystic ovary 
syndrome than in normal women. The qPCR results also 
revealed a higher expression of apolipoprotein A1 in 
proliferative samples compared to luteal.
Immunohistochemical localization of apolipoprotein A1
Positive immunostaining for apolipoprotein A1 was 
observed in the human endometrial tissues [Figure 4]. 
Apolipoprotein A1 was localized in glandular as well as 
stromal compartments of the endometrium. Moderate 
apolipoprotein A1 staining was observed in proliferative 
phase endometria with downregulation of staining in the 
secretory phase of normal women. 
Figure 1: Western blot analysis of apolipoprotein A1 expression in proliferative 
and secretory endometrial samples obtained from healthy fertile women and 
patients with polycystic ovary syndrome. A clear reduction trend was observed 
in apolipoprotein A1 expression of normal samples. The results also showed 
lower expression of apolipoprotein A1 in luteal samples compared to proliferative 
samples. (a) Different letters denote significant differences (b) 1, polycystic ovary 
syndrome; 2, proliferative; 3, luteal. (P value < 0.05)
Figure 2: Expression of apolipoprotein A1 gene in human endometrial tissue. 
Forward and reverse primers produced a specific product with the specific 
predicted size. (P value < 0.05)
Figure 3: qPCR was used to quantify apolipoprotein A1 mRNA expression 
in endometrial biopsies of 10 healthy fertile women and 10 polycystic ovary 
syndrome women obtained in the proliferative and luteal phases. The figure 
shows mean ± SEM of normalized apolipoprotein A1 expression. Apolipoprotein 
A1 level was significantly increased in the endometrial samples of polycystic ovary 
syndrome women compared to normal females. There was also a significantly 
higher apolipoprotein A1 expression in proliferative samples compared to luteal 
samples. Different letters denote significant differences. (P value < 0.05)
Figure 4: Immunohistochemistry for apolipoprotein A1 using endometrial 
samples from PCOS patients (a) and normal women during proliferative phase 
(b) and secretory phase (c). Positive staining is brown and negative staining is 
blue. Insets show blocking of the antiapolipoprotein A1 antibody with its specific 
peptides. Bar = 50 µm
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It is interesting that glandular epithelium and stroma in the 
endometrium of patients with polycystic ovary syndrome 
showed a significantly higher expression of apolipoprotein 
A1 when compared with their respective counterparts in 
the endometrium of normal women.
In the endometrium of women with polycystic ovary 
syndrome, strong staining for apolipoprotein A1 was 
observed in the glandular epithelium with weaker staining 
in the stroma. 
DISCUSSION
Polycystic ovary syndrome is associated with infertility not 
only to anovulation but also to endometrial dysfunction.[9,17] 
Despite many recent advances in assisted reproduction 
techniques even with the selection of good quality embryos, 
the rate of success is mainly limited because of implantation 
failures.[7,8,18] Endometrial factors at the molecular level have 
been suggested to explain implantation failure and poor 
reproductive potential of patients with polycystic ovary 
syndrome.[1,7] 
In women with polycystic ovary syndrome, dyslipidemia 
and lipoprotein abnormalities are common metabolic 
disorders.[19,20] Apolipoprotein A1 is the main protein 
component of high-density lipoprotein (HDL). [11,21] 
Dysregulation of apolipoprotein A1 levels have been reported 
in a variety of diseases such as preeclampsia, endometriosis, 
and repeated implantation failure.[2,12] There are no reports 
describing apolipoprotein A1 expression and function in 
the endometria of women with polycystic ovary syndrome. 
In this study, we assessed the endometrial expression of 
apolipoprotein A1 as a potential biomarker of nonreceptive 
endometria in patients with polycystic ovary syndrome 
without pharmacological treatment. The results showed a 
higher endometrial apolipoprotein A1 mRNA and protein 
expression in women with polycystic ovary syndrome 
compared to fertile women. We also confirmed the presence 
and determined the localization of apolipoprotein A1 in the 
endometrial tissue using immunohistochemistry. Our work 
revealed that endometrial apolipoprotein A1 expression 
specifically in the glandular epithelium was upregulated in 
patients with polycystic ovary syndrome compared to normal 
subjects. However, immunohistochemical staining is a 
qualitative technique and as such is not ideal for quantitative 
analysis; so the results were verified by western blot as a 
semi-quantitative technique.
Recent studies performed on human endometrial samples 
have revealed that elevated apolipoprotein A1 levels 
are associated with unexplained infertility and also 
repeated implantation failure.[2,14] Nyalwidhe et al.[13] 
demonstrated that apolipoprotein A1 is consumed by 
human preimplantation embryos suggesting a possible role 
in implantation. Indeed, embryos with the highest likelihood 
of implantation consume or metabolize apolipoprotein A1, 
which prepares a suitable microenvironment with low 
apolipoprotein A1 levels for successful implantation.[13] In an 
in vitro experiment, apolipoprotein A1 was also found to be 
have a higher expression in nondecidualized cells compared 
to decidualized stromal cells.[14] Thus, important negative 
effects can be predicted for apolipoprotein A1 in the 
initiation and maintenance of the window of implantation. 
Apolipoprotein A1 also has anti-inflammatory properties 
including inhibition of interleukin 1 (IL-1) and tumor 
necrosis factor alpha (TNFα) production, and suppression 
of neutrophil degranulation.[22,23] Inflammatory processes 
are implicated in the pathophysiology of endometriosis. 
Upregulation of endometrial apolipoprotein A1 is observed 
in women with endometriosis.[22] 
Moreover, at the time of implantation, the maternal 
endometrium shows characteristics of an acute aseptic 
inflammatory response.[24,25] Inflammatory cytokines and 
adhesion molecules that are expressed by the endometrium 
and embryo are essential for the appropriate interaction 
between the embryo and the endometrium for successful 
pregnancy.[24,25] Apolipoprotein A1 has the ability to inhibit 
the synthesis of inflammatory cytokines and adhesion 
molecules, such as selectins, that have essential roles in the 
embryo implantation.[23,26-29] Another potential mechanism 
through which apolipoprotein A1 contributes to the 
implantation failure may be via inhibition of angiogenesis. 
Tissue remodeling and angiogenesis are two crucial events 
during implantation and decidualization.[24] Apolipoprotein 
A1 has inhibitory effects on angiogenesis and tissue 
remodeling by downregulation of matrix metalloproteinase 
(MMP)-9, vascular endothelial growth factor (VEGF)/basic 
fibroblast growth factor (bFGF) production, and dendritic 
cell function.[30-32]
Our study demonstrates that apolipoprotein A1 expression 
in human endometria significantly changes during the 
menstrual cycle with minimum level in the secretory 
phase, coincident with the receptive phase (window of 
implantation). It appears that sex hormones regulate the 
expression of apolipoprotein A1 in a reverse manner. There is 
evidence that apolipoprotein A1 is upregulated by estradiol 
and is downregulated by progesterone.[33,34] Progesterone 
may protect the endometrium against the detrimental 
effects of apolipoprotein A1 during the critical period 
of the receptivity window. Endometrial apolipoprotein 
A1 expression is strongly inhibited by human chorionic 
gonadotropin (hCG), which is a key requirement for the 
promotion of implantation.[2] Thus, hCG treatment may 
improve uterine receptivity and pregnancy rate in in vitro 
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fertilization (IVF) patients with polycystic ovary syndrome 
by decreasing apolipoprotein A1 levels.
In summary, the present study provides a novel insight 
into the mechanism of implantation failure and subfertility 
associated with polycystic ovary syndrome condition. 
Elevated apolipoprotein A1 levels can be considered as a 
biomarker for nonreceptive endometrium in patients with 
polycystic ovary syndrome. Further investigation should 
be performed to clarify the major clinical applications of 
this protein.
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